Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Open Access
- 1 September 2011
- journal article
- Published by Taylor & Francis Ltd in International Journal of General Medicine
- Vol. 4, 657-60
- https://doi.org/10.2147/ijgm.s23920
Abstract
Peer reviewed article authored by (Mahamid M, Paz K, Reuven M, Safadi R). Read article or submit your manuscript for publishing.Keywords
This publication has 12 references indexed in Scilit:
- Role of IL-6 trans-signaling in CCl4 induced liver damageBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Activation of interleukin-6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regenerationLiver Transplantation, 2010
- Anakinra for rheumatoid arthritisEmergencias, 2009
- Liver failure after major hepatic resectionJournal of Hepato-Biliary-Pancreatic Surgery, 2008
- Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid ArthritisAnnals of Internal Medicine, 2008
- Safety of extended treatment with anakinra in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2006
- Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateArthritis & Rheumatism, 2004
- Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular riskJournal of Thrombosis and Haemostasis, 2003
- What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.2002
- The effects of treatment with interleukin‐1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritisRheumatology, 2001